Dose daily Chicago Jury Orders Abbott Laboratories to Pay $70 Million in Premature Infant Formula Case By: Dose Daily News Bureau Date: April 12, 2026 Share post: FacebookXPinterestWhatsApp TagsAbbottInfantLawsuit Previous articleSun Pharma’s $12B Organon Bid Signals India’s Boldest Global Pharma ExpansionNext articleViksit Bharat Shiksha Bill Sparks Debate: What It Means for India’s Scientific and Pharma Ecosystem Dose Daily News Bureauhttps://dosedailynews.com/ LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment. I want inI've read and accept the Privacy Policy. Sahajanand Medical Technologies Secures Health Canada Class IV Licence for Supraflex Cruz™️ Stent System, Entering Canadian Market Dose Daily News Bureau - September 12, 2026 Lundbeck Receives U.S. FDA Orphan Drug Designation for Investigational Therapy in Endogenous Cushing’s Syndrome Breaking News U.S. FDA Grants Accelerated Approval for Bayer’s Sevabertinib as First-Line Therapy in Advanced HER2-Mutant NSCLC Following 75% Response Rate Breaking News MSD Inaugurates New Technology Centre in Hyderabad to Drive Global Healthcare Innovation and Digital Capabilities Breaking News Bharat Technology Announces BT-PHARMACON 2K26 with Focus on Indigenous Pharma Innovation Breaking News ChrysCapital to Acquire 20-25% Stake in Linux Laboratories for ₹600 Crore Breaking News Related articles Breaking News Sahajanand Medical Technologies Secures Health Canada Class IV Licence for Supraflex Cruz™️ Stent System, Entering Canadian Market Sahajanand Medical Technologies (SMT), a leading global medical device company, announced that it has received a Class IV... Breaking News Lundbeck Receives U.S. FDA Orphan Drug Designation for Investigational Therapy in Endogenous Cushing’s Syndrome H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to... Breaking News U.S. FDA Grants Accelerated Approval for Bayer’s Sevabertinib as First-Line Therapy in Advanced HER2-Mutant NSCLC Following 75% Response Rate Bayer announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for sevabertinib, an oral,... Breaking News MSD Inaugurates New Technology Centre in Hyderabad to Drive Global Healthcare Innovation and Digital Capabilities MSD (Merck & Co., Inc.), one of the world's leading global life sciences companies, has officially inaugurated its...